Dravet syndrome: Insights into seizure and speech progression from registry data

1:1
Analysis of registry data offers critical insights into the progression of seizures and speech development in patients with Dravet syndrome.

This study utilises patient registry data to track the natural history of Dravet syndrome, focusing on how seizure frequency and speech abilities evolve over time. The findings provide a baseline for evaluating the efficacy of future therapeutic interventions.

Acces this publication (pdf)
Epilepsy & Behaviour

Year of publication

2025

Source

Epilepsy & Behavior

Link to cite

Acces to Link >

Author

elporte M, Verbeeck J, Brambilla I, Zimmermann G, Molenberghs G, Nabbout R, et al.

You might also be interested in

Genetic Mapping

ERDERA unites 10 000 rare disease datasets in a single, secure European resource

In its first year, ERDERA has brought together 10 000 harmonised genomic and phenotypic datasets from unsolved rare disease cases across Europe, creating a secure, standardised and scalable resource.
Medicines

EMA starts review of Tavneos for rare autoimmune diseases GPA and MPA

The European Medicines Agency has begun a formal review of Tavneos (avacopan) after emerging information raised questions about the integrity of key clinical trial data supporting its EU authorisation, with potential implications for adults living with rare autoimmune vasculitis.
Young Patients Training

ERDERA opens call for young rare disease advocates to join training in Paris

Taking place on 23–25 April at Institut Imagine in Paris
Scientific paper

Human genomics technologies in clinical studies – the research landscape: report on the 1990–2024 period

Published on 14 December, this WHO technical document maps global trends in registered clinical studies using human genomic technologies from 1990 to 2024, including patterns of inclusion and equity.

ERDERA's

search form